Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Low incidence of agvhd with ptcy, tacrolimus and post-engraftment low dose ATG-based GvHD prophylaxis in haplo-identical donor transplantation and establish of new predict score for grade II-iv agvhd

View Full Paper
Ask AI
Bookmark
Share

Authors

JHJiong Hu

Discussion

Loading...

Member takes

Overview

Allogeneic HSCT shows reduced aGvHD in hematological malignancies using tacrolimus, suggesting new risk models.

Key Points

  • To validate the low incidence of acute graft-versus-host disease (aGvHD) with a specific prophylaxis regimen and identify its clinical risk factors.
  • Included 210 subjects undergoing allogeneic HSCT for hematological malignancies with haplo-identical donors.
  • Used the Ruijin protocol combining post-transplantation cyclophosphamide, tacrolimus, and low dose anti-thymocyte globulin for GvHD prophylaxis.
  • Conducted univariate and multivariate analysis to identify risk factors for aGvHD.
  • Developed the Ruijin score to classify patients into risk groups based on identified variables.
  • The incidence of 100-day grade II-IV aGvHD was 14.0% and grade III-IV was 3.2%.
  • Donor age (≥37) and CD34+ cell dose (<9.2x106/kg) were independent predictors for grade II-IV aGvHD.
  • The Ruijin score classified patients into three risk groups with significantly different aGvHD incidences (p=0.003).
  • Validation in an independent cohort showed similar aGvHD incidences and confirmed the Ruijin score's stratification ability.

Cite This Study

Jiong Hu (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d86ehttps://doi.org/10.1182/blood-2025-4224
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effect of GVHD prophylaxis on renal function and survival outcomes in allogeneic hematopoietic cell transplant patients with pre-existing renal impairment2025
  2. 2Randomized trial of GvHD Prophylaxis in Haploidentical PBSC Transplantation: ATG, PTCy, and Low-Dose Combination Therapy2026 · 5 citations
  3. 3Exploring the efficacy and safety of low-dose ATG combined with fractionated low-dose ptcy in preventing gvhd after allogeneic hematopoietic stem cell transplantation2025 · 1 citations
  4. 4Factors associated with acute and chronic graft-versus-host disease after unrelated donor hematopoietic cell transplantation using posttransplant cyclophosphamide-based GVHD prophylaxis2025
  5. 5Incidence, Risk Factors and Therapy Response of Acute Graft-versus-Host Disease after Postransplant Cyclophosphamide2024